Synthetic self‐adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy

Synthetic self‐adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy

Abstract The tumor‐associated glycoprotein Mucin 1 (MUC1) is aberrantly glycosylated on cancer cells and is considered a promising target for antitumor vaccines. The weak immunogenicity and low sequence homology of mouse mucins and human MUC1 are the main obstacles for the development of vaccines. H...

Full description

Bibliographic Details
Main Authors: Yang Zhou, Xinru Li, Yajing Guo, Ye Wu, Lixin Yin, Luyun Tu, Sheng Hong, Hui Cai, Feiqing Ding
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:MedComm
Subjects:
cancer vaccine
MUC1 glycopeptide
multivalent strategy
self‐adjuvanted vaccine
Online Access:https://doi.org/10.1002/mco2.484

Internet

https://doi.org/10.1002/mco2.484

Similar Items